Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

NCT01822509 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01822509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2013
Completion date
June 10, 2021
Enrollment
71 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell transplant recipient, myeloproliferative neoplasm, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent hematologic malignancy, recurrent hodgkin lymphoma, recurrent myelodysplastic syndrome, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma